Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Nocturnal masked hypertension tied to higher mortality risk

02 Mar 2025

A recent study has found that in patients with masked hypertension, the mortality risk is not the same for all subtypes and entails night-time blood pressure (BP) elevation, either isolated or with daytime elevation. On the other hand, daytime masked hypertension does not appear to significantly contribute to an increased risk of death.

Nocturnal masked hypertension tied to higher mortality risk

02 Mar 2025

BP-lowering meds help improve hypertension outcomes even in frail individuals

02 Mar 2025

In older adults with hypertension, the presence of frailty does not appear to reduce the effectiveness of antihypertensive treatment, according to a study.

BP-lowering meds help improve hypertension outcomes even in frail individuals

02 Mar 2025

Weight loss plays crucial role in diabetes remission

02 Mar 2025

Bodyweight loss appears to have a strong, independent dose-response association with type 2 diabetes (T2D) remission among people with obesity or overweight, according to the results of a meta-analysis.

Weight loss plays crucial role in diabetes remission

02 Mar 2025

APOSTEL 8: Tocolytic benefit for threatened preterm birth called into question

01 Mar 2025 bởi

In the management of threatened preterm birth between 30 and 34 weeks of gestation, atosiban falls short of improving neonatal outcomes when compared with placebo, according to the results of the APOSTEL 8 trial.

APOSTEL 8: Tocolytic benefit for threatened preterm birth called into question

01 Mar 2025

Comorbid hypertension, diabetes up CVD, death risks

01 Mar 2025

The dual presence of hypertension and diabetes in an individual puts them at increased risks of cardiovascular disease (CVD) and all-cause mortality beyond those associated with either condition alone, reveals a study.

Comorbid hypertension, diabetes up CVD, death risks

01 Mar 2025

Sotagliflozin: First SGLT inhibitor to show ischaemic benefit

01 Mar 2025

The dual sodium–glucose co-transporter (SGLT) 1/2 inhibitor sotagliflozin appears to reduce the risk of major adverse cardiovascular events (MACE), especially myocardial infarction and stroke—a benefit that has not been previously observed with other drugs of the same class—in patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk, according to the secondary analysis of the SCORED trial.

Sotagliflozin: First SGLT inhibitor to show ischaemic benefit

01 Mar 2025

JAK inhibitors tied to high remission rates in older adults with IBD

01 Mar 2025 bởi

Treatment with Janus kinase (JAK) inhibitors, particularly tofacitinib and upadacitinib, was associated with high rates of clinical, endoscopic, and histologic remission in older adults with moderate-to-severe inflammatory bowel disease (IBD), according to a study presented at CCC 2025.

JAK inhibitors tied to high remission rates in older adults with IBD

01 Mar 2025

Ustekinumab vs vedolizumab for older IBD patients: MACE not different, but mortality lower

28 Feb 2025 bởi

In the real-world treatment of older adults with inflammatory bowel disease (IBD), the cardiovascular safety of ustekinumab is similar to that of vedolizumab, with no significant difference in the risk of major adverse cardiovascular events (MACE). However, ustekinumab is associated with a reduced risk of all-cause mortality.